Sensorion Announced Outcomes from Shareholder Meeting in Montpellier

MONTPELLIER, France–(BUSINESS WIRE)–May 13, 2025–Sensorion, a biopharmaceutical company focused on developing treatments for inner ear diseases, recently published the results of its combined Shareholders’ General Meeting held on May 12, 2025.

During the meeting, shareholders voted on several key resolutions aimed at guiding the company’s strategic direction. Notably, the shareholders approved the re-election of three members to the board of directors and approved the company’s annual financial report.

“The continued support from our shareholders is crucial as we advance our mission to develop innovative therapies for hearing loss,” said Sensorion CEO, Dr. Nitin Sood. “We remain committed to enhancing our research and expanding our pipeline of potential treatments.”

In addition to the board re-elections, the meeting addressed new initiatives designed to bolster investor engagement and highlight the company’s upcoming clinical programs.

Sensorion plans to leverage these resolutions to further enhance its research capabilities and foster partnerships that could accelerate the development of its therapeutic candidates. As the company moves forward, it will be announcing additional details regarding its projects in the coming months.